NOV Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 84.40 |
| 52 Week High | DKK 138.48 |
| 52 Week Low | DKK 71.62 |
| Beta | 0.19 |
| 1 Month Change | 8.32% |
| 3 Month Change | -16.44% |
| 1 Year Change | -25.91% |
| 3 Year Change | 84.89% |
| 5 Year Change | 219.88% |
| Change since IPO | 1,321.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| NOV | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 12.5% | 0.6% | -0.6% |
| 1Y | -25.9% | -16.8% | 14.8% |
Return vs Industry: NOV underperformed the German Pharmaceuticals industry which returned -16.2% over the past year.
Return vs Market: NOV underperformed the German Market which returned 14.9% over the past year.
Price Volatility
| NOV volatility | |
|---|---|
| NOV Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: NOV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NOV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 76,826 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NOV fundamental statistics | |
|---|---|
| Market cap | €375.05b |
| Earnings (TTM) | €13.54b |
| Revenue (TTM) | €38.95b |
27.7x
P/E Ratio9.6x
P/S RatioIs NOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOV income statement (TTM) | |
|---|---|
| Revenue | DKK 290.40b |
| Cost of Revenue | DKK 43.56b |
| Gross Profit | DKK 246.84b |
| Other Expenses | DKK 145.86b |
| Earnings | DKK 100.99b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | 22.75 |
| Gross Margin | 85.00% |
| Net Profit Margin | 34.78% |
| Debt/Equity Ratio | 66.9% |
How did NOV perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield50%
Payout RatioDoes NOV pay a reliable dividends?
See NOV dividend history and benchmarks| Novo Nordisk dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Apr 01 2025 |
| Days until Ex dividend | 34 days |
| Days until Dividend pay date | 38 days |
Does NOV pay a reliable dividends?
See NOV dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 08:30 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novo Nordisk A/S is covered by 68 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |